Kurt Graves, former Intarcia Therapeutics CEO
Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA denied
The last members of its executive team have moved on, the phone number at its Boston-based HQ has been shut off, and as of earlier …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
